Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SHR-A1904 versus investigator's choice second-line chemotherapy in CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20243935Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of garetatug rezetecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Hengrui Therapeutics. Started Nov 2024; status: active.
02
Drugs
garetatug rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20243935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243935.